Evidence map›Paper›PMID 33498681›Full record

ArticleCancers2021

Immunophenotype of Gastric Tumors Unveils a Pleiotropic Role of Regulatory T Cells in Tumor Development.

Sara Rocha, Afonso P Basto, Marieke E Ijsselsteijn, Sara P Teles, Maria M Azevedo, Gilza Gonçalves, Irene Gullo, Gabriela M Almeida, Joaquín J Maqueda, Marta I Oliveira and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Role of lysine-specific demethylase 1 in immunotherapy of gastric cancer: An update.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  5. Article
  6. Article
  7. Immunotherapy for advanced gastric cancer.World journal of methodology · 2023
    Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Sara Rochai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-5390-3807
Afonso P BastoiMM-Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Marieke E IjsselsteijnDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Sara P Telesi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-7409-9651
Maria M Azevedoi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.
Gilza GonçalvesDepartment of Pathology, Faculty of Medicine of the University of Porto (FMUP), 4200-319 Porto, Portugal.
Irene Gulloi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0003-3377-0530
Gabriela M Almeidai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0001-8712-7394
Joaquín J Maquedai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-0800-4167
Marta I OliveiraInternational Iberian Nanotechnology Laboratory, 4715-330 Braga, Portugal.
Fátima Carneiroi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-1964-1006
João T BarataiMM-Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Luís GraçaiMM-Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Noel F C C de MirandaDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Joana Carvalhoi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.
Carla Oliveirai3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0001-8340-2264
Universidade do Porto · PTUniversity of Lisbon · PTLeiden University Medical Center · NLi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTInternational Iberian Nanotechnology Laboratory · PT

Funding

COMPETE 2020 - POCI, Lisboa Portugal Regional Operational Program (Lisboa2020), Algarve Portugal Regional Operational Program (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through ERDF, and by FCT GenomePT project (POCI-01-0145-FEDER-022184)ERDF, POCI and FCT Project CANCERSTEMEuropean Union's Horizon 2020 research and innovation program Marie Skłodowska-Curie grant agreement No. 722148 to Train-EV projectFCT PhD Programs and by Programa Operacional Potencial Humano (POCH) BiotechHealth Programe (Doctoral Program on Cellular and Molecular Biotechnology Applied to Health SciencesFEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Program for Competitiveness and Internationalisation (POCI), PORTUGAL 2020, Portuguese funds through Portuguese Science & Technology Foundation (FCT) / Ministér "Institute for Research and Innovation in Health Sciences" (POCI-01-0145-FEDER-007274)Fundação para a Ciência e a Tecnologia FCT fellowship PD/BD/128406/2017 to SR, and Junior Research contract to JC (regulated by the decree-law 57/2016 emended by law 57/2017)Fundação para a Ciência e a Tecnologia IPATIMUP integrates the i3S Research Unit, which is partially supported by FCTFundação para a Ciência e a Tecnologia Project Ref. PTDC/BBB-ECT/2518/2014H2020 European Research Council NFCCdM has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No. 852832).IPATIMUP Board of Directors "The role of gastric cancer cell-derived extracellular vesicles"Norte Portugal Regional Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF Project CANCER Ref. NORTE-01-0145-FEDER-000029 and DOCnet Ref. NORTE-01-0145-FEDER-000003)
6 · The paper itself

Abstract

Gastric cancer (GC) patients display increased regulatory T cell (Tregs) numbers in peripheral blood and among tumor-infiltrating lymphocytes. Nevertheless, the role of Tregs in GC progression remains controversial. Here, we sought to explore the impact of Tregs in GCs with distinct histology, and whether Tregs can directly influence tumor cell behavior and GC development. We performed a comprehensive immunophenotyping of 82 human GC cases, through an integrated analysis of multispectral immunofluorescence detection of T cells markers and patient clinicopathological data. Moreover, we developed 3D in vitro co-cultures with Tregs and tumor cells that were followed by high-throughput and light-sheet imaging, and their biological features studied with conventional/imaging flow cytometry and Western blotting. We showed that Tregs located at the tumor nest were frequent in intestinal-type GCs but did not associate with increased levels of effector T cells. Our in vitro results suggested that Tregs preferentially infiltrated intestinal-type GC spheroids, induced the expression of IL2Rα and activation of MAPK signaling pathway in tumor cells, and promoted spheroid growth. Accumulation of Tregs in intestinal-type GCs was increased at early stages of the stomach wall invasion and in the absence of vascular and perineural invasion. In this study, we proposed a non-immunosuppressive mechanism through which Tregs might directly modulate GC cells and thereby promote tumor growth. Our findings hold insightful implications for therapeutic strategies targeting intestinal-type GCs and other tumors with similar immune context.

Indexed as

gastric cancermolecular regulationregulatory T cellstumor-infiltrating CD4 T cells

Identifiers

PMID33498681
PMCPMC7865950
OpenAlexW3121524271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.